NFE2L2 and hepatocellular carcinoma: Mutations in NFE2L2 (Nrf2) and KEAP1 that prevent Nrf2 degradation are two of the most frequently observed mutations in human HCC (3% and 5% of cases respectively), suggesting this pathway may be a driver of tumorigenesis in the liver [96].